Arrowhead develops RNA interference (RNAi) therapeutics that silence disease-causing genes using its proprietary Targeted RNAi Molecule (TRiM) platform, enabling treatment of previously undruggable disease drivers that small molecules and antibodies cannot effectively address. The company generates revenue through direct commercialization of approved RNAi drugs and through licensing and collaboration agreements with major biopharmaceutical partners like Takeda, Amgen, GSK, Sarepta, and Novartis, receiving both upfront payments and ongoing royalties on out-licensed programs to fund internal pipeline development. Arrowhead maintains a clinical-stage pipeline of multiple drug candidates in development across cardiovascular disease, liver disease, neurodegeneration, and rare genetic disorders, supported by a patent portfolio covering RNAi triggers, delivery technologies, and platform innovations.